Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

被引：2408

作者：

Nathan, David M. ^{[1
]}

Buse, John B. ^{[8
]}

Davidson, Mayer B. ^{[7
]}

Ferrannini, Ele ^{[6
]}

Holman, Rury R. ^{[5
]}

Sherwin, Robert ^{[3
,4
]}

Zinman, Bernard ^{[2
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02114 USA

[2] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada

[3] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA

[4] Yale Univ, Sch Med, Yale Ctr Clin Invest, New Haven, CT 06510 USA

[5] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Diabet Trials Unit, Oxford, England

[6] Univ Pisa, Dept Internal Med, Pisa, Italy

[7] Charles R Drew Univ Med & Sci, Clin Ctr Res Excellence, Los Angeles, CA 90059 USA

[8] Univ N Carolina, Sch Med, Chapel Hill, NC USA

来源：

DIABETES CARE | 2009年 / 32卷 / 01期

关键词：

DIPEPTIDYL PEPTIDASE-4 INHIBITOR; INTENSIVE INSULIN THERAPY; IMPROVED GLYCEMIC CONTROL; MICROVASCULAR COMPLICATIONS; CARDIOVASCULAR EVENTS; COMBINATION THERAPY; EXENATIDE EXENDIN-4; BLOOD-GLUCOSE; DRUG-THERAPY; METFORMIN;

D O I：

10.2337/dc08-9025

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The consensus algorithm for the medical management of type 2 diabetes was published in August 2006 with the expectation that it would be updated, based on the availability of new interventions and new evidence to establish their clinical role. The authors continue to endorse the principles used to develop the algorithm and its major features. We are sensitive to the risks of changing the algorithm cavalierly or too frequently, without compelling new information. An update to the consensus algorithm published in January 2008 specifically addressed safety issues Surrounding the thiazolidinediones. In this revision, we focus on the new classes of medications that now have more clinical data and experience.

引用

页码：193 / 203

页数：11

共 92 条

[31] Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes [J].

Goldstein, Barry J. ;

Feinglos, Mark N. ;

Lunceford, Jared K. ;

Johnson, Jeremy ;

Williams-Herman, Debora E. .

DIABETES CARE, 2007, 30 (08) :1979-1987

[32] SULFONYLUREAS IN NIDDM [J].

GROOP, LC .

DIABETES CARE, 1992, 15 (06) :737-754

[33]

Group D.C.C.T., 1993, NEW ENGL J MED, V329, P978

[34] Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [J].

Grundy, SM ;

Cleeman, JI ;

Merz, CNB ;

Brewer, HB ;

Clark, LT ;

Hunninghake, DB ;

Pasternak, RC ;

Smith, SC ;

Stone, NJ .

CIRCULATION, 2004, 110 (02) :227-239

[35] MATURITY ONSET DIABETES-MELLITUS - RESPONSE TO INTENSIVE DIETARY MANAGEMENT [J].

HADDEN, DR ;

MONTGOMERY, DAD ;

SKELLY, RJ ;

TRIMBLE, ER ;

WEAVER, JA ;

WILSON, EA ;

BUCHANAN, KD .

BMJ-BRITISH MEDICAL JOURNAL, 1975, 3 (5978) :276-278

[36] EPIDEMIOLOGIC CORRELATES OF NIDDM IN HISPANICS, WHITES, AND BLACKS IN THE UNITED-STATES POPULATION [J].

HARRIS, MI .

DIABETES CARE, 1991, 14 (07) :639-648

[37]

Heine RJ, 2005, ANN INTERN MED, V143, P559, DOI 10.7326/0003-4819-143-8-200510180-00006

[38]

Hirsch I., 2005, Clinical Diabetes, V23, P78, DOI DOI 10.2337/DIACLIN.23.2.78

[39] Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide [J].

Holstein, A ;

Plaschke, A ;

Egberts, EH .

DIABETES-METABOLISM RESEARCH AND REVIEWS, 2001, 17 (06) :467-473

[40]

Home PD, N ENGL J MED, V357, P28

← 1 2 3 4 5 6 7 8 9 10 →